Education
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma (GB:0SGC)
:0SGC
0SGC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.39 - $4.68
Previous CloseN/A
Volume724.00
Average Volume (3M)437.00
Market Cap
$579.84M
Enterprise Value$606.61M
Total Cash (Recent Filing)$83.97M
Total Debt (Recent Filing)$3.87M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
May 01, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding189,491,680
10 Day Avg. Volume0
30 Day Avg. Volume437
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)87.41
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.92
Enterprise Value/Ebitda-8.07
Forecast
1Y Price Target
$5.00Price Target Upside50.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Arbutus Biopharma News
PremiumCompany Announcements
Genevant and Arbutus File Global Patent Lawsuits Against Moderna
PremiumCompany Announcements
Arbutus Biopharma Overhauls Board and Appoints New CEO---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceManagement estimates its cash holdings to sufficiently fund its operations through the first quarter of 2028, allowing for the full funding of the upcoming imdusiran Phase 2b trial.
Leadership And ManagementThe appointment of Lindsay Androski as the new CEO is seen as a strategic move, given her focus on LNP litigation.
Bears Say
Legal ChallengesLNP litigation process continues, with ongoing legal challenges against Pfizer/BioNTech and Moderna.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.99% Insiders
10.50% Mutual Funds
20.24% Other Institutional Investors
58.07% Public Companies and Individual Investors
0SGC FAQ
What was Arbutus Biopharma’s price range in the past 12 months?
Arbutus Biopharma lowest share price was $2.39 and its highest was $4.67 in the past 12 months.
What is Arbutus Biopharma’s market cap?
Arbutus Biopharma’s market cap is $579.84M.
When is Arbutus Biopharma’s upcoming earnings report date?
Arbutus Biopharma’s upcoming earnings report date is May 01, 2025 which is in 50 days.
How were Arbutus Biopharma’s earnings last quarter?
Arbutus Biopharma released its earnings results on Nov 06, 2024. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.094 by -$0.006.
Is Arbutus Biopharma overvalued?
According to Wall Street analysts Arbutus Biopharma’s price is currently Undervalued.
Does Arbutus Biopharma pay dividends?
Arbutus Biopharma does not currently pay dividends.
What is Arbutus Biopharma’s EPS estimate?
Arbutus Biopharma’s EPS estimate is -0.08.
How many shares outstanding does Arbutus Biopharma have?
Arbutus Biopharma has 189,491,680 shares outstanding.
What happened to Arbutus Biopharma’s price movement after its last earnings report?
Arbutus Biopharma reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.094. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Arbutus Biopharma?
Currently, no hedge funds are holding shares in GB:0SGC
---
Arbutus Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (50.60% Upside)
$5.00 (50.60% Upside)
Blogger Sentiment
Bullish
GB:0SGC Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.50%
12-Months-Change
Fundamentals
Return on Equity
-67.81%
Trailing 12-Months
Asset Growth
-11.47%
Trailing 12-Months
Company Description
Arbutus Biopharma
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
---
0SGC Stock 12 Month Forecast
Average Price Target
$5.00
▲(50.60% Upside)
Technical Analysis
Gilead Sciences
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Moderna
―
Best Analysts Covering 0SGC
1 Year
1 Year Success Rate
14/34 ratings generated profit
1 Year Average Return
+3.61%
reiterated a buy rating 10 days ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +3.61% per trade.
---